Sabyasachi Das1, Subhankar Manna1, Bhaskar Saha2, Amiya Kumar Hati3, Somenath Roy1. 1. Immunology and Microbiology Laboratory, Department of Human Physiology with Community Health, Vidyasagar University, Midnapore, West Bengal. 2. National Centre for Cell Science, Ganeshkhind, Pune. 3. Calcutta School of Tropical Medicine, Kolkata, West Bengal, India.
Abstract
BACKGROUND: Artesunate-sulfadoxine-pyrimethamine (ASSP) is the frontline artemisinin combination therapy (ACT) in India. Random, irrational, subtherapeutic artemisinin doses and self-medication with ACT along with predominance of sulfadoxine-pyrimethamine resistance parasite invoked a strong possibility of emerging artemisinin-resistant malaria parasites. METHODS: This study involved 226 patients with uncomplicated Plasmodium falciparum infection who had successfully completed the 42 days follow-up after ASSP combination therapy from April 2014 to January 2016. We assessed the ASSP treatment efficacy by evaluating parasite clearance half-life, pfkelch13, and other (pfdhfr, pfdhps, pfmdr1, pfcrt) gene mutations and survival of parasites as detected by an ex vivo ring-stage survival assay (RSA). FINDINGS: Slow-clearing infections with longer parasite clearance half-lives (>5 hours) were observed in 12% isolates. Cure rate after ASSP treatment was declining to about 84.1%. ASSP failure was recorded in 15.9% (early treatment failure, 7.9%; late treatment failure, 7.9%) of isolates. In sum, 24 patients (10.6%) had parasite clearance half-lives greater than 5 hours with pfkelch13 polymorphism after 441 codon; in 15 of those patients (6.6%), parasites had not cleared by 72 hours after initiation of therapy. Median ex vivo ring-stage survival rate of these isolates was very high (12.2%; 95% confidence interval [CI], 10.9-13.8) from that of cured patients (0.9%; 95% CI, 0.09-1.07). Of these 15 patients, 13 patients had pfkelch13 G625R polymorphism, whereas 2 patients contained R539T polymorphism. As per the World Health Organization guideline, these 15 isolates were true artemisinin-resistant isolates. INTERPRETATION: Identification of artemisinin-resistant isolates in India together with new mutations and increasing combination therapy failures blow alarms for urgent malaria control.
BACKGROUND: Artesunate-sulfadoxine-pyrimethamine (ASSP) is the frontline artemisinin combination therapy (ACT) in India. Random, irrational, subtherapeutic artemisinin doses and self-medication with ACT along with predominance of sulfadoxine-pyrimethamine resistance parasite invoked a strong possibility of emerging artemisinin-resistant malaria parasites. METHODS: This study involved 226 patients with uncomplicated Plasmodium falciparum infection who had successfully completed the 42 days follow-up after ASSP combination therapy from April 2014 to January 2016. We assessed the ASSP treatment efficacy by evaluating parasite clearance half-life, pfkelch13, and other (pfdhfr, pfdhps, pfmdr1, pfcrt) gene mutations and survival of parasites as detected by an ex vivo ring-stage survival assay (RSA). FINDINGS: Slow-clearing infections with longer parasite clearance half-lives (>5 hours) were observed in 12% isolates. Cure rate after ASSP treatment was declining to about 84.1%. ASSP failure was recorded in 15.9% (early treatment failure, 7.9%; late treatment failure, 7.9%) of isolates. In sum, 24 patients (10.6%) had parasite clearance half-lives greater than 5 hours with pfkelch13 polymorphism after 441 codon; in 15 of those patients (6.6%), parasites had not cleared by 72 hours after initiation of therapy. Median ex vivo ring-stage survival rate of these isolates was very high (12.2%; 95% confidence interval [CI], 10.9-13.8) from that of cured patients (0.9%; 95% CI, 0.09-1.07). Of these 15 patients, 13 patients had pfkelch13 G625R polymorphism, whereas 2 patients contained R539T polymorphism. As per the World Health Organization guideline, these 15 isolates were true artemisinin-resistant isolates. INTERPRETATION: Identification of artemisinin-resistant isolates in India together with new mutations and increasing combination therapy failures blow alarms for urgent malaria control.
Authors: Theresa Hermann; Patrick Hochegger; Johanna Dolensky; Werner Seebacher; Robert Saf; Marcel Kaiser; Pascal Mäser; Robert Weis Journal: Pharmaceuticals (Basel) Date: 2021-04-27
Authors: Rob W van der Pluijm; Rupam Tripura; Richard M Hoglund; Aung Pyae Phyo; Dysoley Lek; Akhter Ul Islam; Anupkumar R Anvikar; Parthasarathi Satpathi; Sanghamitra Satpathi; Prativa Kumari Behera; Amar Tripura; Subrata Baidya; Marie Onyamboko; Nguyen Hoang Chau; Yok Sovann; Seila Suon; Sokunthea Sreng; Sivanna Mao; Savuth Oun; Sovannary Yen; Chanaki Amaratunga; Kitipumi Chutasmit; Chalermpon Saelow; Ratchadaporn Runcharern; Weerayuth Kaewmok; Nhu Thi Hoa; Ngo Viet Thanh; Borimas Hanboonkunupakarn; James J Callery; Akshaya Kumar Mohanty; James Heaton; Myo Thant; Kripasindhu Gantait; Tarapada Ghosh; Roberto Amato; Richard D Pearson; Christopher G Jacob; Sónia Gonçalves; Mavuto Mukaka; Naomi Waithira; Charles J Woodrow; Martin P Grobusch; Michele van Vugt; Rick M Fairhurst; Phaik Yeong Cheah; Thomas J Peto; Lorenz von Seidlein; Mehul Dhorda; Richard J Maude; Markus Winterberg; Nguyen Thanh Thuy-Nhien; Dominic P Kwiatkowski; Mallika Imwong; Podjanee Jittamala; Khin Lin; Tin Maung Hlaing; Kesinee Chotivanich; Rekol Huy; Caterina Fanello; Elizabeth Ashley; Mayfong Mayxay; Paul N Newton; Tran Tinh Hien; Neena Valecha; Frank Smithuis; Sasithon Pukrittayakamee; Abul Faiz; Olivo Miotto; Joel Tarning; Nicholas P J Day; Nicholas J White; Arjen M Dondorp Journal: Lancet Date: 2020-03-11 Impact factor: 202.731
Authors: Barbara H Stokes; Satish K Dhingra; Kelly Rubiano; Sachel Mok; Judith Straimer; Nina F Gnädig; Ioanna Deni; Kyra A Schindler; Jade R Bath; Kurt E Ward; Josefine Striepen; Tomas Yeo; Leila S Ross; Eric Legrand; Frédéric Ariey; Clark H Cunningham; Issa M Souleymane; Adama Gansané; Romaric Nzoumbou-Boko; Claudette Ndayikunda; Abdunoor M Kabanywanyi; Aline Uwimana; Samuel J Smith; Olimatou Kolley; Mathieu Ndounga; Marian Warsame; Rithea Leang; François Nosten; Timothy Jc Anderson; Philip J Rosenthal; Didier Ménard; David A Fidock Journal: Elife Date: 2021-07-19 Impact factor: 8.140